Drop Testosterone (T) on Day 1
FIRMAGON®—as a GnRH antagonist—is the only hormone therapy of its kind approved to treat advanced prostate cancer (APC).
FIRMAGON immediately lowered T, nearly 90% on the first day
By day 28 of treatment, both FIRMAGON and Lupron Depot® (leuprolide acetate) achieved equivalent testosterone levels.
FIRMAGON gets you to T goal quickly
96% of FIRMAGON patients reached goal testosterone levels by day 3
Lupron Depot initially increased testosterone levels—65% by the third day, compared to a 94% reduction with FIRMAGON. Some patients may require additional medication to prevent a testosterone surge with Lupron Depot.
TESTOSTERONE LEVELS IN THE FIRST 28 DAYS OF THERAPY
Lupron Depot (N=201)
FIRMAGON dropped PSA levels*
PSA reduction follows testosterone suppression. FIRMAGON dropped PSA levels by 95% by month 3.
FIRMAGON is proven to maintain PSA suppression through 12 months of treatment
PSA level is a nonspecific measurement that may indicate cancer progression. These results should be evaluated with caution because of the broad range of patient types in the clinical study. No evidence has shown that the speed at which PSA declines is related to clinical benefit. Therefore, PSA level should not be seen on its own as evidence of the effectiveness of FIRMAGON.
Lupron Depot is a registered trademark of ABBVIE ENDOCRINE INC.
FIRMAGON is approved for ALL stages of advanced prostate cancer
Have A Voice
Every month is an opportunity for you to connect with your treatment team
Make monthly visits matter by getting involved in your treatment plan.